Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: Centers for Disease Control and Prevention
Journal: Emerging Infectious Diseases
Languages: English
Types: Article
Subjects: Dispatch, HIV, wc_503_41, wc_503_4, AIDS-related opportunistic infections, immune restoration disease, immunosuppression, wc_503, qv_268.5, Mycobacterium microti

Classified by OpenAIRE into

mesheuropmc: animal diseases
We describe a severely immunosuppressed HIV-1-positive man in whom immune restoration disease associated with pulmonary infection caused by Mycobacterium microti developed after antiretroviral treatment. The diagnosis was made by using convenient spoligotyping techniques, but invasive investigations were required to exclude a tumor.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Goyal M, Saunders NA, van Embden JD, Young DB, Shaw RJ. Differentiation of Mycobacterium tuberculosis isolates by spoligotyping and IS6110 restriction fragment length polymorphism. J Clin Microbiol. 1997;35:647-51.
    • 2. Cavanagh R, Begon M, Bennett M, Ergon T, Graham IM, de Haas PEW, et al. Mycobacterium microti infection (vole tuberculosis) in wild rodent populations. J Clin Microbiol. 2002;40:3281-5.
    • 3. Wells AQ, Oxon DM. Tuberculosis in wild voles. Lancet. 1937;1:1221.
    • 4. Horstkotte MA, Sobottka I, Schewe CK, Schafer P, Laufs R, RuschGerged S, et al. Mycobacterium microti llama-type infection presenting as pulmonary tuberculosis in a human immunodeficiency virus-positive patient. J Clin Microbiol. 2001;39:406-7.
    • 5. Niemann S, Richter E, Dalügge-Tamm H, Schlesinger H, Graupner D, Königstein B, et al. Two cases of Mycobacterium microti-derived tuberculosis in HIV-negative immunocompetent patients. Emerg Infect Dis. 2000;6:539-42.
    • 6. Foudraine NA, van Soolingen D, Noordhoek GT, Reiss P. Pulmonary tuberculosis due to Mycobacterium microti in a human immunodeficiency virus-infected patient. Clin Infect Dis. 1998;27:1543-4.
    • 7. Van Soolingen D, van der Zanden AGM, de Haas PEW, Noordhoek GT, Kiers A, Foudraine NA, et al. Diagnosis of Mycobacterium microti infections among humans by using novel genetic markers. J Clin Microbiol. 1998;36:1840-5.
    • 8. Huard RC, Oliveira Lazzarini LC, Butler WR, van Soolingen D, Ho JL. PCR-based method to differentiate the subspecies of the Mycobacterium tuberculosis complex on the basis of genomic deletions. J Clin Microbiol. 2003;41:1637-50.
    • 9. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis. 2005;5:361-73.
    • 10. DeSimone JA, Pomerantz RJ, Babichak TJ. Inflammatory reactions in HIV-1 infected patients after initiation of highly active antiretroviral therapy. Ann Intern Med. 2000;133:447-54.
    • 11. Bartley PB, Allworth AM, Eisen DP. Mycobacterium avium complex causing endobronchial disease in AIDS patients after partial immune restoration. Int J Tuberc Lung Dis. 1999;3:1132-6.
    • 12. Price P, Mathiot N, Krueger R, Stone S, Keane NM, French M. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. J Clin Virol. 2001;22:279-87.
    • 13. French MA, Price P, Stone SF. Immune restoration disease after retroviral therapy. AIDS. 2004;18:1615-27.
    • 14. Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIVassociated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis. 2004;190:1670-6.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article